Tryptophan and Behavior Therapy for Cocaine Abuse - 1

This study has been completed.
Sponsor:
Collaborator:
Johns Hopkins University
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000324
First received: September 20, 1999
Last updated: November 3, 2005
Last verified: August 2005
  Purpose

The purpose of this study is to assess the efficacy of tryptophan vs. placebo, and voucher payments vs. a control condition, in the treatment of cocaine dependence.


Condition Intervention Phase
Cocaine-Related Disorders
Drug: Tryptophan
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Tryptophan and Behavior Therapy for Cocaine Abuse

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Side effects
  • Retention
  • Cocaine use
  • Cocaine craving
  • Other drug use
  • Psychosocial functioning

Estimated Enrollment: 200
Study Start Date: March 1997
Estimated Study Completion Date: April 2001
Detailed Description:

This clinical trial uses a 2 by 2 design to compare tryptophan to placebo, and voucher incentives vs. a control condition, in the outpatient treatment of cocaine dependence- using a relapse prevention model of treatment intervention.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Cocaine dependent

Exclusion Criteria:

  • Physically dependent on drugs of abuse other than cocaine
  • Significant medical or psychiatric illness (besides substance abuse disorder)
  • Pregnant
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000324

Locations
United States, Maryland
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States, 21224
Sponsors and Collaborators
Johns Hopkins University
Investigators
Principal Investigator: Eric C Strain, M.D. Johns Hopkins University
  More Information

Publications:
Jones H.E., Johnson, R.E., Bigelow G.E., Strain E.C. Differences at treatment entry between opioid-dependent and cocaine-dependent males and females. Addictive Disorders and Their Treatment 3:110-121, 2004.

ClinicalTrials.gov Identifier: NCT00000324     History of Changes
Other Study ID Numbers: NIDA-10754-1, R01-10754-1
Study First Received: September 20, 1999
Last Updated: November 3, 2005
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Tryptophan
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 16, 2014